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Abstract
Background Microbiotical dysbiosis induced by a Wes-
tern diet seems to be associated with an increased risk of
developing colorectal cancer (CRC). Few other factors
with an effect on the colonic microbiota and their associ-
ation with CRC have been evaluated.
Aim We investigated whether the use of antibiotics is
associated with CRC risk.
Methods Data on the use of antibiotics and comedication
were extracted from a health insurance database for sub-
jects with a diagnostic-related group for CRC between
2006 and 2011 and four age- and sex-matched controls.
Antibiotic use was categorized according to the number of
prescriptions during a 5-year follow-up period (1–6 years
prior to CRC). Multivariable conditional binary logistic
regression analysis was used to estimate odds ratios (ORs)
and 95 % confidence intervals (95 % CIs) for different
levels of use.
Results A total of 4029 cases (47 % male, mean age at
diagnosis 71 ± 11 years) and 15,988 controls were inclu-
ded. Antibiotics had been prescribed to 2630 (65.3 %)
cases and 10,234 (64.0 %) controls (p = 0.13). An
increasing use of antibiotics was associated with an
increasing risk of CRC [multivariable OR for high (C8
prescriptions) vs. no prescriptions: 1.26, 95 % CI
1.11–1.44, p-trend \0.01]. For each increase of 5 pre-
scriptions, the OR for CRC was 1.05 (95 % CI 1.01–1.09).
Conclusion We found an association between the use of
antibiotics, especially when used frequently, and the risk of
developing CRC. Further studies are needed to establish
under which conditions the use of antibiotics increases the
risk of developing CRC.
Keywords Colorectal cancer  Antibiotics  Microbiota 
Pharmacoepidemiology
Introduction
Colorectal cancer (CRC) is the third most common cancer
in men and second most common cancer in women
worldwide [1]. Most cases of CRC develop according to
the adenoma–carcinoma sequence, which is characterized
by the accumulation of genetic and epigenetic mutations
leading to benign premalignant lesions and eventually
cancer [2]. Important risk factors associated with CRC
include lifestyle factors, such as smoking, limited physical
activity, and obesity, and a Western diet which is rich in
animal fat, red and processed meat, and poor in fibers [3].
In the past few years, an increasing interest has emerged
on the role of the gut microbiota in the development of
CRC. The human microbiota consists of approximately
1014 bacterial cells of 500–1000 different species and is
important for the defense against pathogens, the metabo-
lization of polysaccharides, the production of certain vita-
mins and plays a key role in maintaining a healthy immune
system [4]. Furthermore, the colonic microbiota ferments
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undigested carbohydrates from fibers into short-chain fatty
acids including butyrate, acetate, and propionate [5, 6]
which are the preferred energy source of the colon mucosa
and possess anti-inflammatory, anti-proliferative, and anti-
carcinogenic properties [7–14]. High intakes of meat and
animal fat, on the other hand, increase the bacterial pro-
duction of genotoxic hydrogen sulfide and the secretion of
bile acids which are metabolized into carcinogenic sec-
ondary bile acids by 7a-dehydroxylating bacteria [15, 16].
Only a few studies have investigated the association
between the colonic microbiota and CRC development.
These studies show important differences in the composi-
tion of the colon microbiota between low and high CRC
risk populations based on their diet. For example, a reduced
number of short-chain fatty acid-producing bacteria, such
as the anti-inflammatory Faecalibacterium prausnitzii from
the Clostridium cluster IV and Eubacterium/Roseburia
species from cluster XIVa [17], and an increase in sec-
ondary bile acid-producing species are found in high CRC
risk populations [15, 18]. Furthermore, in CRC patients
compared to healthy controls, short-chain fatty acid-pro-
ducing bacteria have been found to be depleted [19, 20]
while the proinflammatory Fusobacterium and Porhy-
romonas genera were increased [19]. In another study in
which stools of CRC patients and healthy subjects were
investigated, an increase in Bacteroides–Prevotella popu-
lations was demonstrated compared to healthy controls
[21].
These findings suggest a potentially important role for
the gut microbiota in the development of CRC. It may well
be possible that other factors, besides diet, known to induce
a disbalance of the gut microbiota are associated with an
increased risk of developing CRC. In this regard, the use of
antibiotics may be of interest since its use may seriously
affect the diversity of the colonic microbiota. We therefore
hypothesize that the (frequent) use of antibiotics is asso-
ciated with an increased CRC risk. In the current study, we
investigated whether the use of antibiotics and specific
classes of antibiotics is associated with the risk of devel-
oping CRC in a population-based cohort. Secondly, we
investigated potential effect modification by other factors
that have an effect on the gut microbiota or have been
found to be associated with CRC risk.
Methods
Data Collection
For this nested case–control study, we used data of the
Achmea Health Database in the Netherlands, which is a
healthcare claim database covering approximately 1.2
million subjects (8 % of the Dutch population). The
database contains anonymized data on demographic char-
acteristics, reimbursed diagnostic-related groups (DRGs),
and medication. The population insured by the Achmea
Health Insurance Company represents the urbanized area
of the Netherlands with regard to age, gender, and
socioeconomic status [22].
DRGs were introduced in the Netherlands in 2006 and
are based on the International Classification of Disease, 9th
revision (ICD-9). They are reimbursed per episode of care
provided by secondary care physicians for inpatient and
outpatient hospital care services. Data on DRGs were
available between January 2006 and December 2011 and
contained information on the colorectal cancer diagnosis
and date of DRG registration, which usually is the first visit
to the physician but can also be a follow-up visit.
Data on reimbursed medication were available between
January 2001 and December 2011 and contained infor-
mation on type of drug (ATC codes), date the drug was
filled, number of daily defined doses (DDDs), the pre-
scribed daily dose (PDD), and the prescribing physician,
i.e., primary or secondary care. The DDD is the average
maintenance dose per day for a drug used for its main
indication in adults and is defined by the WHO Collabo-
rating Centre for Drug Statistics Methodology [23]. The
PDD is the fraction of DDD per day that is actually pre-
scribed by the treating physician. In the Netherlands,
antibiotics can only be obtained with a prescription of a
physician and these prescriptions are registered in the
Achmea Health Database for subjects insured with this
insurance company. However, medication prescriptions
during hospitalizations are not registered in the database.
This study was approved by the scientific and privacy
committee of the Achmea Health Insurance Company and
was performed in accordance with the ethical guidelines of
our institute.
Study Population
The complete database was searched for adult (C18 years)
subjects with a DRG for CRC between January 2006 and
December 2011. An incidence CRC case was defined as a
subject with at least two DRGs for CRC or one DRG for
CRC surgery, in which the first DRG was not registered
within the first 1.5 years of follow-up. This 1.5-year clean
period was chosen to minimize the risk of including
prevalent CRC cases and was based on the recommended
follow-up of patients with CRC every 6–12 months until
5 years after initial treatment with curative intent or more
frequently in case of palliative treatment (according to the
national guidelines at that time [24, 25]). The date of CRC
diagnosis was defined as the date of first DRG registration.
Each case was matched with regard to sex and date of birth
to four randomly selected controls without a DRG for CRC
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and with at least the same period of follow-up as their
matched case. Both cases and controls were required to
have at least 6 years of complete follow-up before CRC
diagnosis. Cases and controls that at some point during
follow-up had a DRG for inflammatory bowel disease were
excluded.
Antibiotic Use
Antibiotics included were tetracyclines (ATC codes J01A),
amphenicols (ATC codes J01B), penicillins (ATC codes
J01C), cephalosporins (ATC codes J01D), sulfonamides
and trimethoprim (ATC codes J01E), macrolides (ATC
codes J01F), aminoglycosides (ATC codes J01G), quino-
lones (ATC codes J01M), imidazoles (ATC codes J01XD),
nitrofuran derivates (ATC codes J01XE), and others (ATC
codes J01XA, J01XB, J01XC, J01XX). The number of
days for which antibiotics were prescribed was calculated
as prescribed days = DDD/PDD. For prescriptions with an
unknown DDD (3.6 %) or PDD (7.7 %), values were
imputed with SAS PROC MI procedure, under the missing
at random assumption and based on ATC code, primary or
secondary care prescribing physician, sex, and age. The use
of antibiotics was measured as the number of prescriptions
and the prescribed number of days during a 5-year period
in the period 1–6 years prior to CRC diagnosis. Subjects
were categorized as nonusers and very low (1st–50th per-
centile), low (51st–75th percentile), intermediate (76th–
90th percentile), and high (above 90th percentile) users of
antibiotics. For the analyses of anti-anaerobic agents and
subtypes of antibiotics, we categorized subjects as nonusers
and low (1st–75th percentile), intermediate (76th–90th
percentile), and high (above 90th percentile) users.
Covariates
Covariates included in this study were sex, age (continuous),
insulin-dependent diabetes (ATC codes A10A, no/yes),
insulin-independent diabetes (ATC codes A10B, no/yes),
and the use of proton pump inhibitors (ATC codes A02BC),
acetylsalicylic acids (ATC codes B01AC06 and B01AC08),
nonsteroidal anti-inflammatory drugs (ATC codes M01A),
lipid-lowering agents (ATC codes C10AA, C10BA, and
C10BX), estrogens (ATC codes G03AA, G03AB, G03FA,
and G03FB), and immunosuppressive drugs (ATC codes
L04A). The cumulative number of prescribed days per drug
was categorized as none and the 1st–75th, 76th–90th, and
above 90th percentile within users.
Statistical Analyses
The use of antibiotics and comedication in cases and
matched controls was assessed over a 5-year period
between 1 and 6 years prior to CRC diagnosis. Medication
use within 1 year prior to CRC diagnosis was not included
in the analysis to minimize the risk of reversed causation.
Differences in baseline characteristics were compared
between cases and controls and expressed in means ±
standard deviations (SDs), medians (interquartile range—
IQR), and frequencies whenever applicable. Student’s t
test and Mann–Whitney U test were used for continuous
variables and Pearson Chi-square test for categorical
variables.
Univariable and multivariable binary logistic regression
analyses, conditioned on the matching factors sex and date
of birth, were used to calculate the odds ratio (OR) and
95 % confidence intervals (95 % CIs) for the use of
antibiotics on a categorical and continuous scale and the
risk of developing CRC. Linear trends over different cat-
egories were computed using median levels of antibiotic
use within the categories in all subjects. Two models were
tested: (1) a univariable conditioned model on the matching
factors age and sex and (2) a multivariable model condi-
tioned on these matching factors and adjusted for factors
statistically significantly associated with the outcome or the
use of antibiotics.
Effect modification between the use of antibiotics and
other factors that may affect the gut microbiota or that have
previously been found to be associated with CRC risk was
tested by adding multiplicative interaction terms to the
model and using likelihood ratio tests for interaction. For
these analyses, we used the interaction terms of overall
antibiotic use (number of prescriptions, categorical) with
insulin-independent diabetes (no/yes), insulin-dependent
diabetes (no/yes), proton pump inhibitors (no/yes), acetyl-
salicylic acids (no/yes), nonsteroidal anti-inflammatory
drugs (no/yes), statins (no/yes), estrogens (no/yes), and
immunosuppressive drugs (no/yes).
Sensitivity analyses were performed to study possible
reversed causation by assessing the use of antibiotics
between 2–7 years and 3–8 years prior to CRC diagnosis.
Statistical analyses were conducted with SAS 9.2 (SAS
Institute Inc, Cary, USA). Two-sided p values\0.05 were
considered statistically significant.
Results
Between January 2006 and December 2011, 8141 subjects
were identified with a DRG for CRC. After the exclusion of
subjects with a DRG for inflammatory bowel disease
(n = 88), prevalent CRC cases (n = 3518), or subjects
with less than 6 years of follow-up (n = 506) before the
first DRG, 4029 incident CRC cases remained available for
the analysis. These cases were matched to 15,988 controls
without inflammatory bowel disease or CRC.
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Baseline Characteristics
Baseline characteristics are shown in Table 1. Of all CRC
cases, 47 % were male and mean age at diagnosis was
71 ± 11 years. No statistically significant differences were
found between cases and controls with regard to insulin-
independent (p = 0.32) and insulin-dependent (p = 0.45)
diabetes and use of proton pump inhibitors (p = 0.14),
acetylsalicylic acids (p = 0.09), lipid-lowering agents
(p = 0.56), estrogens (p = 0.48), and immunosuppressive
drugs (p = 0.52). However, subjects with CRC used less
nonsteroidal anti-inflammatory drugs (p\ 0.01) compared
to controls. All these covariates were statistically signifi-
cantly (p\ 0.001) associated with an increasing use of
antibiotics.
The most frequently prescribed antibiotics included
penicillins (31.6 %), tetracyclines (20.7 %), quinolones
(13.9 %), macrolides (9.6 %), sulfonamides and trimetho-
prim (9.6 %), and nitrofuran derivates (12.4 %). Other
antibiotics, including cephalosporins, aminoglycosides,
amphenicols, and imidazoles, were rarely prescribed
(combined 2.2 %). During the 5-year follow-up period,
antibiotics had been prescribed to 2630 (65.3 %) CRC
cases and 10,234 (64.0 %) controls (p = 0.13). When
excluding nonusers, the median number of prescriptions of
antibiotics was 2 (IQR 1–5) versus 2 (1–5) times
(p = 0.07) for cases and controls, respectively, corre-
sponding to 17 (IQR 8–35) versus 16 (8–34) days of use
(p = 0.10).
Use of Antibiotics and Colorectal Cancer Risk
A high (C8) number of prescriptions of antibiotics were
associated with an increased risk of CRC (see Table 2).
Univariable OR was 1.23 (95 % CI 1.08–1.40, p-trend
\0.01) when comparing a high (C8) number versus no
prescriptions and was 1.04 (95 % CI 1.01–1.07) for each
increase of 5 prescriptions. Multivariable analyses adjusted
for all measured potential confounders showed an OR of
1.26 (95 % CI 1.11–1.44, p-trend\0.01) for a high (C8)
number versus no prescriptions and an OR of 1.05 (95 %
CI 1.01–1.09) for each increase of 5 prescriptions.
The analyses for the number of prescribed days yielded
a statistically significantly increased risk of CRC when
antibiotics were used for C70 days versus no use of
antibiotics (univariable OR 1.24, 95 % CI 1.08–1.44, p-
trend\0.01; multivariable OR 1.28, 95 % CI 1.10–1.48, p-
trend\0.01). However, on a continuous scale (per 25 days
increase), no association was found (multivariable OR
1.00, 95 % CI 0.99–1.01).
When specified for anti-aerobic and anti-anaerobic
antibiotics (see Table 3), we found a positive association
between the number of prescriptions and the risk of CRC
for both anti-aerobic [multivariable high (C8) vs. no pre-
scriptions 1.25, 95 % CI 1.08–1.45] and anti-anaerobic
agents [multivariable high (C5) vs. no prescriptions 1.45,
95 % CI 1.07–1.97]. When further categorized by classes
of antibiotics, we found an increased risk for penicillins
[multivariable high (C5) vs. no prescriptions 1.29, 95 % CI
1.06–1.56] and quinolones [multivariable high (C5) vs. no
prescriptions 1.53, 95 % CI 1.19–1.96], but not for tetra-
cyclines, sulfonamides and trimethoprim, macrolides, and
nitrofuran derivates.
Interaction with Other Factors
No statistically significant interactions were observed
between the use of antibiotics and insulin-dependent dia-
betes (p = 0.14), insulin-independent diabetes (p = 0.84),
and the use of proton pump inhibitors (p = 0.59), acetyl-
salicylic acids (p = 0.62), nonsteroidal anti-inflammatory
drugs (p = 0.46), lipid-lowering agents (p = 0.96), estro-
gens (p = 0.57), or immunosuppressive drugs (p = 0.76).
Sensitivity Analysis
Sensitivity analyses to assess for reversed causation
between the use of antibiotics and CRC showed that the
OR increased when a less recent follow-up period was
used. Multivariable ORs were 1.33 (95 % CI 1.08–1.64)
for C8 versus 0 prescriptions and 1.17 (95 % CI 0.95–1.43)
for C70 versus 0 days for antibiotics between 7 and 2 years
and 1.37 (95 % CI 1.10–1.70) for C8 versus 0 prescriptions
and 1.24 (95 % CI 1.00–1.53) for C70 versus 0 days for
antibiotics between 8 and 3 years prior to CRC diagnosis.
Discussion
The results of this nested case–control study indicate that
the use of antibiotics is associated with a dose-dependent
increased risk of developing CRC. The results were similar
for models adjusted for sex and age and models addition-
ally adjusted for comorbidities and comedication. These
positive associations were found for both anti-aerobic and
anti-anaerobic drugs; however, when stratified for different
classes of antibiotics, we observed only statistically sig-
nificant associations for penicillins and quinolones.
Previous studies investigating the association between
the use of antibiotics and cancer risk demonstrated similar
results. A Finnish cohort study including over three million
subjects found relative risks of 1.37 (95 % CI 1.34–1.40)
for developing any cancer and 1.15 (95 % CI 1.04–1.26)
for developing colon cancer when comparing subjects with
C6 prescriptions to those with 0–1 prescriptions over a
3-year period prior to cancer diagnosis [26]. In a recent
258 Dig Dis Sci (2016) 61:255–264
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nested case–control study in which Boursi et al. included
over twenty thousand cases, a dose-dependent increased
CRC risk for subjects who had used penicillins, cephalos-
porins, sulfonamides/trimethoprim, and nitroimidazoles in
the 1–5 years prior to index date [27]. Their findings
remained significant after adjusting for potential con-
founding lifestyle factors, comorbidities, comedication,
and previous screening colonoscopy. Another nested case–
control study by Wang et al. in almost 28,000 patients with
type 2 diabetes also found a positive association between
the use of anti-anaerobic antibiotics and both colon (OR
2.31, 95 % CI 2.12–2.52) and rectal cancer (OR 1.69, 95 %
CI 1.50–1.90), but no association was found for anti-aer-
obic agents [28]. In contrast, in our study, we found a
positive association between the use of anti-aerobic agents
and developing CRC, although this was less pronounced
Table 1 Baseline
characteristics of colorectal







Age (years), mean ± SD 71.4 ± 11.4 71.4 ± 11.4 0.94
Male, n (%) 1896 (47.1) 7527 (47.1) 0.98
Insulin-independent diabetes, n (%) 606 (15.0) 2305 (14.4) 0.32
Insulin-dependent diabetes, n (%) 215 (5.3) 806 (5.0) 0.45
Proton pump inhibitorsa, n (%)
None 2315 (57.5) 9187 (57.5) 0.14
Low 1312 (32.6) 5074 (31.7)
Intermediate 248 (6.2) 986 (6.2)
High 154 (3.8) 741 (4.6)
Acetylsalicylic acida, n (%)
None 2941 (73.0) 11,502 (71.9) 0.09
Low 825 (20.5) 3282 (20.5)
Intermediate 166 (4.1) 708 (4.4)
High 97 (2.4) 796 (3.1)
Nonsteroidal anti-inflammatory drugsa, n (%)
None 1677 (41.6) 6702 (41.9) \0.01
Low 1832 (45.5) 6895 (43.1)
Intermediate 327 (8.1) 1418 (8.9)
High 193 (4.8) 973 (6.1)
Blood lipid-lowering agentsa, n (%)
None 2703 (67.1) 10,779 (67.4) 0.56
Low 987 (24.5) 3872 (24.2)
Intermediate 191 (4.7) 808 (5.1)
High 148 (3.7) 529 (3.3)
Estrogensa, n (%)
None 3917 (97.2) 15,567 (97.4) 0.48
Low 89 (2.2) 311 (1.9)
Intermediate 12 (0.3) 68 (0.4)
High 11 (0.3) 42 (0.3)
Immunosuppressive drugsa, n (%)
None 3966 (98.4) 15,707 (98.2) 0.52
Low 45 (1.1) 213 (1.3)
Intermediate 9 (0.2) 43 (0.3)
High 9 (0.2) 25 (0.2)
SD standard deviation
a Cutoff points are based on the 50th, 75th, and 90th percentile of prescriptions within users: proton pump
inhibitors (1, 922, 1710), acetylsalicylic acid (1, 1740, 1825), nonsteroidal anti-inflammatory drugs (1, 96,
392), blood lipid-lowering agents (1, 1770, 1825), estrogens (1, 661, 953), immunosuppressive drugs (1,
1333, 1825)
b Pearson Chi-square test for categorical variables and Student’s t test for continuous variables
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when compared to anti-anaerobic agents. The gut micro-
biota is predominately composed of anaerobes, and the
findings reported by Wang et al. and those of our study
suggest that particularly the use of anti-anaerobic agents
may promote colorectal tumor growth, although caution is
required when drawing conclusions about possible
explanatory mechanisms.
Whether the observed associations between antibiotics
and cancer risk reflect a causal relation is unclear.
Antibiotics generally have no known genotoxic potential,
and evidence of possible carcinogenic effects of antibiotics
is limited [29]. However, some antibiotics up-regulate
cyclooxygenase-2 and increase the production of pros-
taglandins [30], which are important in inflammatory
responses and are known to promote the development of
CRC [31]. Furthermore, it has been hypothesized that a
depletion of anti-inflammatory and short-chain fatty acid-
producing species, such as Faecalibacterium prausnitzii
and Roseburia, and the abundance of pro-inflammatory
microorganisms, such as Fusobacterium, Porhyromonas,
Enterococcaceae, and Bacteroides–Prevotella, and toxin-
producing species including B. fragilis and some E. coli
strains could change the gut microbiota in a more pro-
carcinogenic environment [27]. This shift is thought to be
dependent on subjects’ age, diet, and pathogen infections,
but it can be hypothesized that the frequent use of antibi-
otics may alter short-chain fatty acid-producing species by
causing a dysbiosis of the colonic microbiota, thereby
increasing the risk of developing CRC [7–14]. The
observed association between the use of antibiotics and
CRC risk in our study could also be caused by unmeasured
confounding factors associated with CRC risk and a higher
use of antibiotics, such as socioeconomic status, smoking,
body mass index, and other lifestyle factors. This is sup-
ported by the relative modest risk estimates that we found
in this study. Nonetheless, when we adjusted for potential
confounding factors associated with lifestyle, including
diabetes and the use of statins, acetylsalicylic acids, and
nonsteroidal anti-inflammatory drugs, the results remained
similar. Similarly, modest risk estimates were found in the
study by Boursi et al. after adjusting for lifestyle factors,
comorbidities, comedication, and previous screening
colonoscopy. An alternative explanation for the findings of
the present study could be that subjects with a weakened
Table 2 Univariable and
multivariable odds ratios for the







OR (95 % CI)
Multivariabled
OR (95 % CI)
Prescriptionsa
None 1399 (34.7) 5754 (36.0) Ref. Ref.
Very low 1328 (33.0) 5245 (32.8) 1.04 (0.96–1.13) 1.05 (0.96–1.14)
Low 549 (13.6) 2250 (14.1) 1.01 (0.90–1.13) 1.02 (0.91–1.14)
Intermediate 358 (8.9) 1413 (8.8) 1.05 (0.92–1.19) 1.06 (0.93–1.22)
High 395 (9.8) 1326 (8.3) 1.23 (1.08–1.40) 1.26 (1.11–1.44)
p-trend \0.01 \0.01
Per 5 prescriptions 1.04 (1.01–1.07) 1.05 (1.01–1.09)
Daysb
None 1399 (34.7) 5754 (36.0) Ref. Ref.
Very low 1243 (30.9) 4971 (31.1) 1.03 (0.95–1.12) 1.03 (0.95–1.13)
Low 711 (17.6) 2722 (17.0) 1.08 (0.97–1.19) 1.09 (0.98–1.21)
Intermediate 377 (9.4) 1550 (9.7) 1.01 (0.89–1.14) 1.02 (0.89–1.16)
High 299 (7.4) 991 (6.2) 1.24 (1.08–1.44) 1.28 (1.10–1.48)
p-trend \0.01 \0.01
Per 25 days 1.00 (0.99–1.01) 1.00 (0.99–1.01)
ORs odds ratios, 95 % CI 95 % confidence interval
a Cutoff points are based on the 50th, 75th, and 90th percentile of prescriptions within users: very low
(1–2), low (3–4), intermediate (5–7), and high (C8)
b Cutoff points are based on the 50th, 75th, and 90th percentile of prescribed number of days within users:
very low (1–15), low (16–34), intermediate (35–70), and high (C70)
c Univariable binary logistic regression analyses conditioned on age and sex
d Multivariable binary logistic regression analyses conditioned on age and sex and adjusted for insulin-
independent diabetes, insulin-dependent diabetes, and the use of proton pump inhibitors, acetylsalicylic
acid, nonsteroidal anti-inflammatory drugs, blood lipid-lowering agents, estrogens, and immunosuppressive
drugs
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Table 3 Univariable and multivariable odds ratios for the cumulative number of prescriptions for specific antibiotic groups and colorectal
cancer risk





OR (95 % CI)
Multivariablef
OR (95 % CI)
Anti-aerobic agentsa,b, n (%)
None 1399 (34.7) 5762 (36.0) Ref. Ref.
Very low 1329 (33.0) 5242 (32.8) 1.05 (0.96–1.14) 1.05 (0.96–1.14)
Low 552 (13.7) 2255 (14.1) 1.01 (0.91–1.13) 1.02 (0.91–1.15)
Intermediate 358 (8.9) 1413 (8.8) 1.05 (0.92–1.19) 1.06 (0.93–1.21)
High 391 (9.7) 1316 (8.2) 1.23 (1.08–1.40) 1.25 (1.10–1.43)
Only anti-aerobic agentsb,c, n (%)
None 1535 (38.1) 6360 (39.8) Ref. Ref.
Very low 1367 (33.9) 5262 (32.9) 1.08 (0.99–1.17) 1.08 (0.99–1.18)
Low 500 (12.4) 2088 (13.1) 1.00 (0.89–1.11) 1.01 (0.90–1.13)
Intermediate 317 (7.9) 1227 (7.7) 1.08 (0.94–1.23) 1.09 (0.95–1.25)
High 310 (7.7) 1051 (6.6) 1.23 (1.07–1.41) 1.25 (1.08–1.45)
Anti-anaerobic agentsd, n (%)
None 3090 (76.7) 12,622 (79.0) Ref. Ref.
Low 772 (19.2) 2842 (17.3) 1.11 (1.02–1.22) 1.12 (1.03–1.23)
Intermediate 110 (2.7) 360 (2.3) 1.25 (1.01–1.55) 1.27 (1.02–1.58)
High 57 (1.4) 164 (1.0) 1.43 (1.05–1.93) 1.45 (1.07–1.97)
Penicillinsd, n (%)
None 2356 (58.5) 9695 (60.6) Ref. Ref.
Low 1251 (31.0) 4821 (30.2) 1.07 (0.99–1.15) 1.08 (0.99–1.16)
Intermediate 271 (6.7) 979 (6.1) 1.14 (0.99–1.32) 1.16 (1.00–1.34)
High 151 (3.7) 493 (3.1) 1.26 (1.05–1.53) 1.29 (1.06–1.56)
Tetracyclinesd, n (%)
None 2871 (71.3) 11,509 (72.0) Ref. Ref.
Low 905 (22.5) 3549 (22.2) 1.02 (0.94–1.11) 1.02 (0.94–1.11)
Intermediate 173 (4.3) 612 (3.8) 1.13 (0.95–1.35) 1.15 (0.96–1.37)
High 80 (2.0) 318 (2.0) 1.01 (0.79–1.29) 1.02 (0.80–1.31)
Sulfonamides and trimethoprimd, n (%)
None 3506 (87.0) 14,085 (88.1) Ref. Ref.
Low 410 (10.2) 1497 (9.4) 1.11 (0.98–1.24) 1.11 (0.99–1.25)
Intermediate 70 (1.7) 238 (1.5) 1.19 (0.91–1.56) 1.19 (0.91–1.56)
High 43 (1.1) 168 (1.1) 1.03 (0.73–1.44) 1.04 (0.74–1.46)
Macrolidesd, n (%)
None 3446 (85.5) 13,696 (85.7) Ref. Ref.
Low 501 (12.4) 1923 (12.0) 1.04 (0.93–1.15) 1.04 (0.93–1.16)
Intermediate 50 (1.2) 254 (1.6) 0.78 (0.57–1.06) 0.78 (0.57–1.06)
High 32 (0.8) 115 (0.7) 1.11 (0.75–1.64) 1.12 (0.75–1.66)
Quinolonesd, n (%)
None 3324 (82.5) 13,464 (84.2) Ref. Ref.
Low 509 (12.6) 1897 (11.9) 1.09 (0.98–1.22) 1.10 (0.99–1.23)
Intermediate 107 (2.7) 385 (2.4) 1.13 (0.91–1.40) 1.14 (0.91–1.42)
High 89 (2.2) 242 (1.5) 1.51 (1.18–1.93) 1.53 (1.19–1.96)
Nitrofuran derivatesd, n (%)
None 3458 (85.8) 13,835 (86.5) Ref. Ref.
Low 415 (10.3) 1612 (10.1) 1.04 (0.92–1.17) 1.04 (0.92–1.17)
Intermediate 93 (2.3) 309 (1.9) 1.21 (0.96–1.54) 1.23 (0.97–1.56)
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immune system are more susceptible for developing cancer
and more frequently develop infections requiring antibi-
otics. In that case, the observed associations may only be
an indicator for an increased cancer risk in general rather
than an effector. This may be why in previous studies
positive associations have been found between the use of
antibiotics and tumors in other organs, such as breast,
prostate, lung, and thyroid cancer and non-Hodgkin’s
lymphoma, which, as far as we currently understand, do not
have an association with the gut microbiota [26, 32–36].
We observed no statistically significant interaction between
the use of antibiotics and other factors that may affect the
gut microbiota or that have previously been reported to be
associated with CRC risk, which suggests that there is no
synergetic effect of antibiotics with diabetes or other
medications. We also did not find evidence for reversed
causation since prolonging the lag time between the last
time point of antibiotic use and CRC diagnosis from 1 to 2
or 3 years had no effect on the results. On the contrary, the
risk estimates increased when a follow-up period further
back in time was employed. This increases the likelihood
of a causal effect since CRC has been estimated to develop
over a period of 8–10 years [37].
The strengths of this study include the large number of
CRC cases and matched controls that were identified in a
health claim database providing high-quality data on the
use of antibiotics and potential confounding medication
and comorbidity. In the Netherlands, antibiotics can only
be obtained with a prescription of a physician and therefore
are registered in the health claim database. Both DRG and
pharmacy registrations are complete and highly accurate
because of the economic function of the database for the
insurance company [22]. Furthermore, compared to most
previous studies, we included a higher number of subjects
from the general population [26, 28, 32].
A limitation of our study is that the diagnosis of CRC
could not be histologically confirmed. Second, as previously
mentioned, there were no data available on potential con-
founding lifestyle factors, which is a limitation of the present
study. Third, antibiotics prescribed during hospitalizations
are not registered in the database. Therefore, we could not
include the antibiotics that are more frequently prescribed
during hospitalization, such as cephalosporins, aminogly-
cosides, and imidazoles. There were also no data available
on whether the dispensed antibiotics were actually used.
Both may have diluted the true size of the association
between antibiotics and CRC risk. Finally, we did not have
data on the microbiota composition of the subjects included
in our study. Combined data on the use of antibiotic agents
and the composition of the gut microbiota could be of
additive value to further detangle the association between
antibiotic use and CRC development. Nevertheless, the
dose-dependent increase and the similar risk estimates for
antibiotic use up to 8 years before diagnosis suggest that a
dysbiosis of the gut microbiota through the use of antibiotics
may partially contribute to the development of CRC.
As of now, there is insufficient evidence to make a
clinical recommendation regarding the use of antibiotics
and CRC risk. The results of our study do, however, sup-
port the idea that a microbiotical disbalance in the col-
orectum may increase the risk of developing CRC. Two
previous studies, of which one in a general population
investigating a shorter exposure period and one only
including subjects with type 2 diabetes, found a positive
association between the use of antibiotics and CRC risk.
These findings are now supported by our study in a general
population. Additional epidemiological studies with long-
term follow-up should focus on the mutual effects of
antibiotic use and lifestyle factors to further elucidate the
association between antibiotic use and CRC risk. Further-
more, observational studies including measurements of the
(changes in) microbiota composition in relation to CRC
risk may provide more insights in the role of the gut
microbiota in the pathogenesis of CRC.
Table 3 continued





OR (95 % CI)
Multivariablef
OR (95 % CI)
High 63 (1.6) 232 (1.5) 1.10 (0.83–1.46) 1.10 (0.83–1.46)
ORs odds ratios, 95 % CI 95 % confidence interval
a Cutoff points are based on the 50th, 75th, and 90th percentile of prescriptions within users: very low (1–2), low (3–4), intermediate (5–7), and
high (C8)
b Including anti-aerobic antibiotics with anti-anaerobic properties
c Excluding anti-aerobic antibiotics with anti-anaerobic properties
d Cutoff points are based on the 75th and 90th percentile of prescriptions within users: low (1–2), intermediate (3–4), and high (C5)
e Univariable binary logistic regression analyses conditioned on age and sex
f Multivariable binary logistic regression analyses conditioned on age and sex and adjusted for insulin-independent diabetes, insulin-dependent
diabetes, and the use of proton pump inhibitors, acetylsalicylic acid, nonsteroidal anti-inflammatory drugs, blood lipid-lowering agents, estro-
gens, and immunosuppressive drugs
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In conclusion, we observed a positive association
between the use of antibiotics, especially when used fre-
quently, and the risk of developing CRC. Whether this
association resembles a causal relation must be investigated
in future studies.
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